Results published in the Journal Immunity share discovery of a new mechanism by which Chi3L1 regulates breast cancer development and progression
This groundbreaking paper deepens the understanding of how CHI3L1 inhibits the body’s natural ability to fight breast cancer tumors. It reveals for the first time another complex pathway by which CHI3L1 inhibits the immune response to cancer, this time by inducing neutrophil recruitment and NETosis, which blocks T cell infiltration. The paper also provides yet another preclinical demonstration of the effectiveness of Ocean’s Anti-CHI3L1 antibody in reducing the tumor growth by targeting CHI3L1 and reversing the T cell blockade. This tumor control pathway, the paper asserts, is likely at work in a range of cancers beyond breast cancer, and “targeting CHI3L1 may promote anti-tumor immunity in various tumor types.”
“This complex work by our colleagues at McGill has provided one of the most exciting discoveries of my lifetime and adds another layer of understanding about the ways in which CHI3L1 functions as a ‘master regulator’ that is not only at work in many cancers, but working in multiple pathways within individual cancers,” commented Dr.
Several publications this year have reinforced the potential of Ocean’s Anti-CHI3L1 immunotherapy in treating aggressive cancers. In April, an independent study published in
In October, results published in bioRxiv by Elias and colleagues at Yale revealed the role of CHI3L1 in the growth of EGFR-mutant non small cell lung cancer (NSCLC), and the importance of CHI3L1 in the pathogenesis of therapeutic resistance in NSCLC. These studies also demonstrated that the anti-CHI3L1 antibody effectively restored therapeutic responsiveness to tyrosine kinase inhibitors (TKI) in drug resistant NSCLC with the combination of Ocean’s antibody and a TKI, stopping human tumor progression by stimulating tumor suppressor genes and inducing tumor cell death. Although these findings were defined in NSCLC, they have potential effectiveness in other EGFR-mutation driven cancers including Glioblastoma and Colon cancer.
“We are excited to see the potential for Ocean’s cancer immunotherapy candidate demonstrated by a range of studies in some of the most aggressive cancers,” said Dr. Chirinjeev Kathuria, Ocean’s Executive Chairman and Founder.
“We are pleased to see additional research about the potential impact of cancer candidate as we continue to move towards filing an IND,” said
Prior research has established that elevated Chi3L1 levels are associated with many cancers, including glioblastoma, and may be targeted therapeutically. Recent studies from
About
To learn more, visit www.oceanbiomedical.com
Forward-Looking Statements
The information included herein and in any oral statements made in connection herewith include “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “estimate,” “plan,” “project,” “forecast,” “intend,” “will,” “expect,” “anticipate,” “believe,” “seek,” “target,” or other similar expressions that predict or indicate future events or trends or that are not statements of historical matters, although not all forward-looking statements contain such identifying words. These forward-looking statements include, but are not limited to, statements regarding estimates and forecasts of financial and performance metrics and expectations. These statements are based on various assumptions, whether or not identified herein, and on the current expectations of the Company’s management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by any investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions.
The announced discoveries were based solely on laboratory and animal studies.
Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside the control of the Company that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. Important factors, among others, that may affect actual results or outcomes include (i) the outcome of any legal proceedings that may be instituted against the Company; (ii) changes in the markets in which the Company competes, including with respect to its competitive landscape, technology evolution, or regulatory changes; (iii) changes in domestic and global general economic conditions; (iv) risk that the Company may not be able to execute its growth strategies; (v) risks related to the ongoing COVID-19 pandemic and response, including supply chain disruptions; (vi) risk that the Company may not be able to develop and maintain effective internal controls; (vii) the risk that the Company may fail to keep pace with rapid technological developments to provide new and innovative products and services or make substantial investments in unsuccessful new products and services; (viii) the ability to develop, license or acquire new therapeutics; (ix) the risk that the Company will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; (x) the risk that the Company experiences difficulties in managing its growth and expanding operations; (xi) the risk of product liability or regulatory lawsuits or proceedings relating to the Company’s business; (xii) the risk of cyber security or foreign exchange losses; (xiii) the risk that the Company is unable to secure or protect its intellectual property.
The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties that are described in the Company’s Annual Report on Form 10-K for the year ended
Ocean Biomedical Media Relations
connect@oceanbiomedical.com
Source:
2023 GlobeNewswire, Inc., source